Osteoporosis Canada - Fracture Liaison Service
  • Home
  • About FLS
    • What is FLS?
    • The Osteoporosis Care Gap
    • OCs Role in Supporting the Implementation of Quality FLSs
    • White Paper: Towards a Fracture-Free Future
  • Canadian FLS Registry
    • Registry Map
    • FLS Registry Submission
  • Tools & resources
    • FLS Toolkit
    • Essential Elements
    • Key Indicators for Canadian FLSs
    • Quality Standards
    • Webinars
    • Join the Canadian FLS Network
  • News
  • Contact us
  • Search
  • Menu Menu

FLS Renewal Form Audit J Weldon (OOS)

FLS Renewal Form Audit J Weldon (OOS)

Step 1 of 5

20%
  • Section 1: Information about your FLS program

    For any questions in filling out this questionnaire, please contact Luanne Schenkels at lschenkels@osteoporosis.ca
Save and continue later by copying this link into a safe place
  • Section 2: Type of FLS

  • (Click only one answer)
Save and continue later by copying this link into a safe place
  • Section 3: FLS Processes

  • (Click only one answer)
  • (Click only one answer)
  • (Click only one answer)
  • (Click only one answer)
  • (Click all that apply)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. • For oral bisphosphonates (alendronate/risedronate), it is defined as: o Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND o Also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
Save and continue later by copying this link into a safe place
  • Section 4: Annual Enrollment Data

  • FRACTURE NUMBERS-of the above number, how many were:

  • a. Hip (proximal femur) fractures
  • b. Wrist (distal radius) fractures
  • c. Shoulder (proximal humerus) fractures
  • d. Pelvic fractures
  • e. Spine/vertebral fractures
Save and continue later by copying this link into a safe place
  • Section 5: Permission

  • Osteoporosis Canada may use aggregate data from this audit for possible publication and/or research purposes. The individual FLS sites would remain completely anonymous in the event of any publication.
Save and continue later by copying this link into a safe place
© Copyright - Osteoporosis Canada - Fracture Liaison Service | Privacy Policy
Scroll to top